How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

238 results for

Emergency Pediatric Dosing 12-14 kilogram

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Final recommendation statement: obesity in children and adolescents: screening.

Final recommendation statement: obesity in children and adolescents: screening. Final recommendation statement: obesity in children and adolescents: screening. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history (...) was chosen as the preferred outcome because it was the only widely available measure that could be used to compare relative degree of excess weight across ages. The BMI z score values associated with the 85th and 95th percentiles according to CDC standards are 1.036 and 1.645, respectively. If BMI z score was not reported, BMI (calculated as weight in kilograms divided by height in meters squared), weight, waist circumference, or BMI percentile were used. The closest follow-up to 12 months was used

2017 National Guideline Clearinghouse (partial archive)

82. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

. Racial and Ethnic Differences in Treatment e61 10.2. Sex-Related Issues e61 10.2.1. Women e62 10.2.2. Pregnancy e62 10.3. Age-Related Issues e63 10.3.1. Older Persons e63 10.3.2. Children and Adolescents e64 11. Other Considerations e64 11.1. Resistant Hypertension e64 11.2. Hypertensive Crises—Emergencies and Urgencies e65 11.3. Cognitive Decline and Dementia e68 11.4. Sexual Dysfunction and Hypertension e69 11.5. Patients Undergoing Surgical Procedures e69 12. Strategies to Improve Hypertension (...) Interventions to Improve Hypertension Control e74 12.4. Improving Quality of Care for Patients With Hypertension e74 12.4.1. Performance Measures e74 12.4.2. Quality Improvement Strategies e74 12.5. Financial Incentives e75 13. The Plan of Care for Hypertension e75 13.1. Health Literacy e76 13.2. Access to Health Insurance and Medication Assistance Plans e76 13.3. Social and Community Services e76 14. Summary of BP Thresholds and Goals for Pharmacological Therapy e77 15. Evidence Gaps and Future Directions

2017 American Heart Association

83. Heart Disease and Stroke Statistics 2017 Update: A Report From the American Heart Association

. . . . . . . . . . . . . . . . . e295 11. Metabolic Syndrome . . . . . . . . . . . . . . . e313 12. Chronic Kidney Disease . . . . . . . . . . . . . e336 Cardiovascular Conditions/Diseases 13. Total Cardiovascular Diseases . . . . . . . . . . e349 14. Stroke (Cerebrovascular Disease). . . . . . . . . e374 15. Global CVD and Stroke . . . . . . . . . . . . . . e414 16. Congenital Cardiovascular Defects and Kawasaki Disease . . . . . . . . . . . . . . . . e423 17. Disorders of Heart Rhythm . . . . . . . . . . . . e440 18. Sudden (...) Cardiac Arrest (Chapter 18) • In the 2015 CARES (Cardiac Arrest Registry to Enhance Survival) National Survival Report for emergency medical services–treated nontrau- matic cardiac arrest, the survival rate to hospital discharge was 10.6% for adults >18 years old, 23.5% for children 13 to 18 years old, 16.6% for children >1 to 12 years old, and 6.2% for children 0. • Coronary artery calcium scores >400 versus 0 are associated with an increased risk for can- cer, chronic kidney disease, pneumonia

Full Text available with Trip Pro

2017 American Heart Association

84. Obesity in Adolescents

1.2%) compared with white adolescents using DMPA ( ). Adolescents who gain weight during the first few doses of DMPA may have a propensity for weight gain with DMPA; adolescents who have a 5% increase in body weight in the first 6 months of DMPA use will gain more weight than those who do not ( ). Adolescents who use contraceptive pills, the patch, the vaginal ring, implant, or IUD do not experience an increase in body weight or a change in body composition ( , ). A 12-month study in females 14 (...) , abdominal pain, diarrhea, vomiting) are dose related and improve with continued use. A meta-analysis of nine randomized clinical trials compared metformin with placebo or other lifestyle interventions in obese adolescents without comorbidities ( ). Study duration averaged 6 months, with a range of 2–12 months. The metformin group had a mean BMI reduction of 1.21–1.42 with no effect on fasting glucose levels. There was no difference in adverse effects between the metformin group and the placebo group

2017 American College of Obstetricians and Gynecologists

85. Dyslipidaemias

Dyslipidaemias We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation 14 October 2016 (...) by this author on: David A Wood (UK) Search for other works by this author on: Jose Luis Zamorano (Spain) Search for other works by this author on: Marie-Therese Cooney (Ireland) Search for other works by this author on: ESC Scientific Document Group Search for other works by this author on: European Heart Journal , Volume 37, Issue 39, 14 October 2016, Pages 2999–3058, Published: 28 August 2016 A correction has been published: Citation Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John

Full Text available with Trip Pro

2016 European Society of Cardiology

86. European Society of Endocrinology Clinical practice guidelines for the care of girls and women with Turner syndrome

, USA 9 Division of Endocrinology, Nemours Children’s Health System, Jacksonville, Florida, USA 10 St Hubert’s Island, New South Wales, Australia 11 Connecticut Children’s Medical Center, Hartford, Connecticut, USA 12 Division of Psychology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA 13 Department of Pediatric Endocrinology, Sophia Children’s Hospital, Rotterdam, The Netherlands 14 Department of Pediatrics, Dordrecht, The Netherlands 15 Department of Pediatrics (...) years to further promote growth (⨁⨁◯◯). R 2.8. We recommend that estrogen replacement should start between 11 and 12 years of age increasing to adult dosing over 2–3 years (⨁⨁⨁◯). R 2.9. We suggest that low-dose estradiol (E2) is the preferred estrogen and that it be administered by a systemic route and that the transdermal route is preferred (⨁◯◯◯). R 2.10. We recommend adding progesterone once breakthrough bleeding occurs, or after 2 years of estrogen treatment (⨁⨁⨁⨁). 3. Fertility, assisted

2017 European Society of Endocrinology

87. Adopting eHealth Solutions: Implementation Strategies

strategy should be initiated early in the planning phase and updated regularly throughout the project . V Recommendation 1 .12: Health care organizations will incorporate usability processes throughout the implementation and adoption of the eHealth solution to enhance individual and organizational efficiencies, effectiveness, and user satisfaction . V Recommendation 1 .13: Project leads will develop a comprehensive education and training plan to enable individuals to learn and integrate the new eHealth (...) solution into their daily routine and workflows . V Recommendation 1 .14: Project leads will collaborate with the steering committee to identify key indicators for monitoring and evaluation and use a comprehensive evaluation framework to guide the project evaluation . III Recommendation 1 .15: Health care organizations will have an ongoing post-implementation operational plan that includes data governance structures and processes that support sustainability and continuous optimization of the eHealth

2017 Registered Nurses' Association of Ontario

88. Drugs That May Cause or Exacerbate Heart Failure

factor for developing HF (RR=8), increasing the estimated risk of HF at 20 years after the first dose to 9.8% (95% CI, 2.2–17.4) and suggesting that pediatric populations are susceptible to cardiomyopathy at much lower cumulative doses than those first identified in adult populations. Furthermore, a meta-analysis of 30 studies including 12 507 pediatric patients identified doses of >45 mg/m 2 given within 1 week as an independent predictor of developing A-HF through multivariate regression analysis (...) slower onset compared with intravenous induction agents in patients with ventricular dysfunction. Intravenous Anesthetics Propofol is a short-acting hypnotic agent with potentiation of gamma-aminobutyric acid receptor activity. It is the most commonly used intravenous anesthetic for the induction (2–2.5 mg/kg) and maintenance (6–12 mg·kg −1 ·h −1 ) of anesthesia and for procedural sedation. Although propofol has both negative inotropic effects and vasodilatory properties proportional to dose

Full Text available with Trip Pro

2016 American Heart Association

89. Contrast-induced Nephropathy

1. Analytic framework comparing the benefits and harms of different methods used to prevent contrast-induced nephropathy in patients receiving low-osmolar or iso-osmolar contrast media 4 Figure 2. Results of the literature search 14 Figure 3. Meta-analysis of high-dose N-acetylcysteine plus IV saline versus IV saline with or without placebo for the prevention of contrast-induced nephropathy 19 Figure 4. Meta-analysis of low-dose N-acetylcysteine plus IV saline versus IV saline with or without (...) bicarbonate versus N-acetylcysteine plus IV saline; 8 RCTs comparing a statin versus IV saline; 5 RCTs comparing a statin plus N-acetylcysteine versus N-acetylcysteine; 6 RCTs comparing statin versus statin, statin by dose, or statins plus other agents; 5 RCTs comparing an adenosine antagonist versus IV saline; 6 RCTs investigating hemodialysis or hemofiltration versus IV saline; 6 RCTs comparing ascorbic acid versus IV saline, and 3 RCTs comparing ascorbic acid to N-acetylcysteine. Although we found many

2016 Effective Health Care Program (AHRQ)

90. Management of Carpal Tunnel Syndrome

Ketoprofen Phonophoresis 10 Therapeutic Ultrasound 11 Laser Therapy 11 Surgical Release Location 11 Surgical Release Procedure 11 Surgical versus Nonoperative 11 Adjunctive Techniques 12 Bilateral versus Staged Carpal Tunnel Release 12 Local versus IV Regional Anesthesia 12 Buffered versus Plain Lidocaine 12 Aspirin Use 13 Preoperative Antibiotics 13 Supervised versus Home Therapy 13 Postoperative Immobilization 13 II. Table of Contents 14 List of Tables 18 Table of Figures 23 III. Introduction 24 (...) - PICO 1 (Physical Tests Versus Reference Standard) 82 Table 11. Diagnostic Quality Evaluations 91 Table 12: Summary of Findings- Index Test Versus AANEM Referenced EDS 93 Table 13: Summary of Findings- Index Test Versus General EDS Methods 94 Table 14: High Quality Studies- PICO 2 (History Interview Topics Versus Reference Standard) 95 Table 15: Moderate Quality Studies- PICO 2 (History Interview Topics Versus Reference Standard) 104 Table 16: Low Quality Studies- PICO 2 (History Interview Topics

2016 American Academy of Orthopaedic Surgeons

91. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

]), bariatric surgery CPGs (11 [EL 4; NE]), healthy eating CPGs (26 [EL 4; NE]), diabetes comprehensive care CPGs (18 [EL 4; NE]; 19 [EL 4; NE]), obesity and nutrition position statements (12 [EL 4; NE]), and other educational programs and white papers (14 [EL 4; NE]).AACE/ACE Obesity CPG, Endocr Pract. 2016;22(Suppl 3) 7 III. METHODS This AACE/ACE CPG on Obesity is developed according to established AACE/ACE methodology for guidelines development (23 [EL 4; NE]; 24 [EL 4; NE]; 25 [EL 4; NE (...) School of Medicine, Internal Medicine, Endocrinology, Pediatrics, Pediatric Endocrinology, New Haven, Connecticut; 7 Walter Reed National Military Medical Center, Diabetes Obesity & Metabolic Institute, Bethesda, Maryland; 8 Assistant Clinical Professor, Mount Sinai School of Medicine, NY, ProHealth Care Associates, Division of Endocrinology, Lake Success, New York; 9 Center for Weight Management, Division of Endocrinology, Diabetes and Metabolism, Scripps Clinic, San Diego, California. Address

2016 American Association of Clinical Endocrinologists

92. Gastroenteritis

– unidentified cause, Dyspepsia – proven functional, Dyspepsia – proven peptic ulcer, Diverticular disease, Gastroenteritis and Scrotal pain and swellings. November 2016 — minor update. Adverse effects of loperamide have been updated to include information in a U.S. Food and Drug Administration (FDA) Drug safety communication, warning that exceeding the maxium dose can cause serious cardiac problems including QT interval prolongation, Torsades de Pointes or other ventricular arrhythmias, syncope, and cardiac (...) , and Escherichia coli 0157. Less commonly implicated are Bacillus species, Cryptosporidium, Entamoeba histolytica, Giardia, and Shigella. In some cases of food poisoning, symptoms are primarily caused by toxins produced by the organism (rather than by the organism itself) [ ; ]. Episodes of diarrhoea can be classified into several categories: Acute diarrhoea is defined as three or more episodes of partially-formed or watery stool in a day, lasting for less than 14 days [ ]. Persistent diarrhoea is an acutely

2019 NICE Clinical Knowledge Summaries

93. Gastrointestinal Complications (PDQ®): Health Professional Version

. Gastrointest Endosc 54 (2): 229-32, 2001. [ ] Martinez-Santos C, Lobato RF, Fradejas JM, et al.: Self-expandable stent before elective surgery vs. emergency surgery for the treatment of malignant colorectal obstructions: comparison of primary anastomosis and morbidity rates. Dis Colon Rectum 45 (3): 401-6, 2002. [ ] Ripamonti C, Bruera E: Palliative management of malignant bowel obstruction. Int J Gynecol Cancer 12 (2): 135-43, 2002 Mar-Apr. [ ] Potluri V, Zhukovsky DS: Recent advances in malignant bowel (...) chemotherapy.[ ] The large and small bowel are very sensitive to ionizing radiation. Although the probability of tumor control increases with the radiation dose, so does the damage to normal tissues. Acute side effects to the intestines occur at approximately 10 Gy. Because curative doses for many abdominal or pelvic tumors range between 50 and 75 Gy, enteritis is likely to occur.[ ] In this summary, unless otherwise stated, evidence and practice issues as they relate to adults are discussed. The evidence

2018 PDQ - NCI's Comprehensive Cancer Database

94. Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®): Health Professional Version

Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®) Health Professional Version PDQ Pediatric Treatment Editorial Board . Published online: October 29, 2018. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of Wilms tumor and other childhood kidney tumors. It is intended as a resource to inform and assist clinicians (...) who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). General Information About Childhood Kidney

2017 PDQ - NCI's Comprehensive Cancer Database

95. Obesity

Obesity Obesity - NICE CKS Share Obesity: Summary The terms 'overweight' and 'obesity' are used to describe excess body fat. Obesity results from an imbalance between energy intake and energy expenditure. Many factors can influence this, including lifestyle, genetics, medical conditions, and medication. Different weight classes are defined according to a person's body mass index (BMI). This is calculated by dividing the person's weight in kilograms by the square of their height in metres (...) activity and behavioural strategies. [ ] QOF indicators QOF indicators Table 1. Indicators related to obesity and overweight in the quality and outcomes framework (QOF) of the General Medical Services (GMS) contract. Indicator Points Payment stages OB002 The contractor establishes and maintains a register of patients aged 18 years and or over with a BMI ≥30 in the preceding 12 months 8 — Source: [ ] QIPP - Options for local implementation QIPP - Options for local implementation No QIPP indicators were

2017 NICE Clinical Knowledge Summaries

96. Infective Endocarditis in Childhood: 2015 Update

Coagulase-negative staphylococci 2 4 12 14 Streptococcus pneumoniae 3 4 7 1 HACEK N/A 5 4 N/A Enterococcus species N/A 7 4 N/A Culture negative 6 7 5 N/A Values indicate percentage of patients in the series. HACEK indicates Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; and N/A, not applicable. After the first year of life, VGS are generally the most frequently isolated organisms in patients with IE caused by underlying congenital heart (...) , with specific attention to the disease as it affects infants and children. In particular, the impact of increased survival for children with congenital heart disease (CHD) on the epidemiology of IE is updated, and newer tools useful for diagnosis and treatment in the pediatric population are reviewed. This review emphasizes changing management perspectives and discussion of new agents that have utility for treatment of resistant organisms. In addition, proper use of the diagnostic microbiology laboratory

Full Text available with Trip Pro

2015 American Heart Association

97. Brodalumab (Kyntheum) - plaque psoriasis

and 224 ml/kg suggests a distribution to the plasma and the extravascular fluid as it is within 2 to 5 times that of plasma volume (45 mL/kg). This is consistent with the known biodistribution of monoclonal antibodies. Evidence of placental transfer of brodalumab was provided by neonatal exposure in some infants at 25 and 90 mg/kg on birth days 14 (both doses) and 28 (90 mg/kg only) and levels were comparable to or slightly higher than maternal serum levels. Brodalumab was present in maternal milk (...) 2.1.4. Clinical presentation 9 2.1.5. Management 9 2.2. Quality aspects 10 2.2.1. Introduction 10 2.2.2. Active Substance 10 2.2.3. Finished Medicinal Product 13 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 14 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 16 2.2.6. Recommendation for future quality development 17 2.3. Non-clinical aspects 17 2.3.1. Introduction 17 2.3.2. Pharmacology 17 2.3.3. Pharmacokinetics 19 2.3.4. Toxicology 20 2.3.5

2017 European Medicines Agency - EPARs

98. Adalimumab (Imraldi) - psoriasis, psoriatic arthritis, axial spondyloarthritis, Crohn?s disease, ulcerative colitis

and the recommended posology of Imraldi correspond with Humira containing 40 mg adalimumab; also the pediatric dosing follows that of EU-Humira, although it is not possible to administer Imraldi to paediatric patients that require less than a full 40 mg dose due to the absence of a vial presentation. 2.2.2. Active Substance Structure Imraldi (adalimumab) is a recombinant human monoclonal antibody, which is typically a "Y"- shaped large glycoprotein consisting of two kappa light chains each with a molecular weight (...) . Disease or condition 11 2.1.2. Biologic features 13 2.2. Quality aspects 14 2.2.1. Introduction 14 2.2.2. Active Substance 14 2.2.3. Finished Medicinal Product 17 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 22 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 22 2.2.6. Recommendation(s) for future quality development 23 2.3. Non-clinical aspects 23 2.3.1. Pharmacology 23 2.3.2. Pharmacokinetics 24 2.3.3. Toxicology 24 2.3.4. Ecotoxicity/environmental

2017 European Medicines Agency - EPARs

99. Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis

Kilogram MAA Marketing Authorisation Application mg Milligram MMRM Mixed Model Repeated Measure N Na ns Number of Patients Not analysed Not specified PASI Psoriasis Area and Severity Index PC Placebo-controlled PD Pharmacodynamics PK Pharmacokinetics PPS Per-protocol set RA Rheumatoid arthritis SAE Serious Adverse Event SAP Statistical Analysis Plan SD SDV Standard deviation Source Data Verification SmPC Summary of Product Characteristics sTNF soluble Tumour Necrosis Factor TEAE Treatment-emergent (...) discussion 9 2.1. Problem statement 9 2.1.1. Disease or condition 9 2.2. Quality aspects 11 2.2.1. Introduction 11 2.2.2. Active substance 11 2.2.3. Finished Medicinal Product 14 2.2.4. Biosimilarity 16 2.2.5. Adventitious agents 22 2.2.6. GMO 23 2.2.7. Discussion on chemical, pharmaceutical and biological aspects 23 2.2.8. Conclusions on the chemical, pharmaceutical and biological aspects 23 2.2.9. Recommendation for future quality development 23 2.3. Non-clinical aspects 23 2.3.1. Introduction 23 2.3.2

2017 European Medicines Agency - EPARs

100. Perinatal care at the threshold of viability

age achieved, (e.g. only if gestation reaches 24 weeks) then administer corticosteroids prior to the specified gestation (i.e. don’t wait until 24 weeks+0 days) • Inform the family that administration does not oblige or necessarily equate to a final decision for life sustaining interventions • Where corticosteroids are indicated, administer: o Betamethasone 11.4 mg IM o 2 nd dose: Give 24 hours after initial dose, however if birth likely within 24 hours, consider repeat dose at 12 hours o Consider (...) administration of additional dose if more than 7 days since initial dose 46 *Refer to Australian pharmacopoeia for complete drug information Queensland Clinical Guideline: Perinatal care at the threshold of viability Refer to online version, destroy printed copies after use Page 20 of 35 5.3 Cardiotocograph monitoring Table 14. Cardiotocograph monitoring Aspect Considerations Context • Physiological control of FHR and resultant cardiotocograph (CTG) trace interpretation differs in the preterm compared

2014 Queensland Health

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>